SCHEMBL7769950

SCHEMBL7769950

FCCOc1ccc(Br)cc1F

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.46
NSD3 Q9BZ95 1/20 0.46
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
KDM1A O60341 1/20 0.40
AAK1 Q2M2I8 2/20 0.39
HTR2A P28223 4/20 0.39
HTR2C P28335 4/20 0.39
HTR2B P41595 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 1/20 0.39
SLC6A4 P31645 1/20 0.38
HPGD P15428 1/20 0.38
USP28 Q96RU2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL848521 0.91 NSD2 (0.45) NSD2NSD3KDM4EPOLBPKM
SCHEMBL3189588 0.87 KDM4E (0.45) NSD2NSD3KDM4EPOLBPKM
SCHEMBL15300823 0.85 KDM4E (0.44) NSD2NSD3KDM4EPOLBPKM
SCHEMBL1824099 0.85 NSD2 (0.46) NSD2NSD3KDM4EPOLBPKM
SCHEMBL4311584 0.85 HTR2A (0.39) NSD2NSD3HTR2AHTR2CHTR2B
SCHEMBL15677337 0.84 KDM4E (0.42) NSD2NSD3KDM4EPOLBPKM
SCHEMBL10458198 0.84 PDE10A (0.41) KDM4EHTR2AHTR2CHTR2BL3MBTL1
SCHEMBL5881114 0.83 HPGD (0.55) NSD2NSD3KDM4EPOLBAAK1
SCHEMBL1821512 0.83 NSD2 (0.45) NSD2NSD3KDM4EPOLBPKM
SCHEMBL27738395 0.83 NSD2 (0.45) NSD2NSD3KDM4EPOLBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109423298-B Novel dibenzothiophene liquid crystal compound and preparation method and application thereof 北京八亿时空液晶科技股份有限公司 2020-09-11 CN disclosed
US-20170002005-A1 Carbazole and Carboline Compounds for Use in the Diagnosis, Treatment, Alleviation or Prevention of Disorders Associated with Amyloid or Amyloid-Like Proteins LIFE MOLECULAR IMAGING LIMITED (GB) 2017-01-05 US disclosed
US-20170002005-A1 Carbazole and Carboline Compounds for Use in the Diagnosis, Treatment, Alleviation or Prevention of Disorders Associated with Amyloid or Amyloid-Like Proteins LIFE MOLECULAR IMAGING LIMITED (GB) 2017-01-05 US disclosed
WO-2015110263-A1 CARBAZOLE AND CARBOLINE COMPOUNDS FOR USE IN THE DIAGNOSIS, TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH AMYLOID OR AMYOLID-LIKE PROTEINS AC IMMUNE SA (CH) 2015-07-30 WO disclosed
EP-0727428-B1 Novel silacyclohexane compounds, preparation thereof, liquid crystal compositions comprising the same, and liquid crystal devices comprising the compositions SHINETSU CHEMICAL CO (JP) 2001-06-06 EP disclosed
US-5665271-A Silacyclohexane compounds, preparation thereof, liquid crystal compositions comprising the same, and liquid crystal devices comprising the compositions SHIN-ETSU CHEMICAL CO., LTD. (JP) 1997-09-09 US disclosed
EP-0727428-A1 Novel silacyclohexane compounds, preparation thereof, liquid crystal compositions comprising the same, and liquid crystal devices comprising the compositions SHIN-ETSU CHEMICAL CO., LTD. (JP) 1996-08-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170002005-A1 Carbazole and Carboline Compounds for Use in the Diagnosis, Treatment, Alleviation or Prevention of Disorders Associated with Amyloid or Amyloid-Like Proteins APP, BACE1, PSEN1 NSD2 3006/4885NSD3 1773/4885KDM4E 3698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.